FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns pharmaceutical composition containing oxytocin and at least one non-ionic cellulose ether, where said non-ionic cellulose ether is hydroxypropyl methylcellulose, and pharmaceutical composition has pH ranging from 3 to 4. Group of inventions also concerns application of at least one non-ionic cellulose ether to improve stability of pharmaceutical composition containing oxytocin; method of treating and/or preventing menopausal disorders, including introduction to subject needing it of therapeutically effective amount of said pharmaceutical composition.
EFFECT: group of inventions provides improved stability of oxytocin compositions, convenience of storage, including at room temperature, and preservation of biological activity for long period of time.
35 cl, 1 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
